Novacyy 2019-05-26 Sd «2027»

The core of its microbiology, hematology, and serology offerings.

The date , fell in the wake of several major corporate actions that reshaped the company's financial health: novacyy 2019-05-26 SD

Its molecular diagnostics unit, which was already gaining traction as a partner for clinical assay development. The core of its microbiology, hematology, and serology

That same month, Novacyt’s Lab21 unit launched six new products in its PathFlow™ range, targeting pathogens like C. difficile and Norovirus. 📉 Financial Performance and Stock Context The core of its microbiology

In early 2019, the company successfully raised approximately €785,000 to fund this expansion, showing strong investor confidence despite its small-cap status at the time.